Graph 1
Vectra Predicts Risk of Radiographic Progression in 1 Year
Myriad Genetics, Inc.
Graph 2
Vectra Predicts Risk of Cardiovascular Events in Patients with RA
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data on the Vectra test at the 2019 ACR/ARP Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA. The key findings are that the Vectra test predicts the risk of radiographic progression (RP) within one year, and the Vectra score, in combination with other clinical measures, predicts the risk of a cardiovascular (CV) event in people with rheumatoid arthritis (RA).
A hallmark feature ofrheumatoid arthritisisinflammation, which increases the risk of joint damage, cardiovascular disease and other comorbidities, said Elena Hitraya, M.D., Ph.D., rheumatologist and chief medical officer at Myriad Autoimmune. The data being presented by our academic collaborators at ACR show that the Vectra test accurately measures inflammation and can help predict patients risk of adverse health outcomes, enabling clinicians to tailor precision treatment plans to achieve better outcomes.
Vectra Posters
Title:Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis.Presenter:Jeff Curtis, M.D., M.S., MPH, University of Alabama at Birmingham.Date:Sunday, Nov. 10, 2019. 9:00-11:00 a.m.Location:Poster 466.
This study evaluated the ability of the Vectra test to predict patients individual percentage risk of RP within one year. The analysis included combined data from 973 patients in four cohorts. The results demonstrate that the adjusted Vectra score was a superior predictor of RP within one year compared to DAS28-CRP, CRP, CDAI and swollen joint count. Additionally, the risk of permanent joint damage increased continuously with the adjusted Vectra score, meaning patients with a low adjusted Vectra score had a one to three percent risk of RP in one year, while patients with a moderate-to-high score had between seven and 47 percent risk (Graph 1). Based on these new data, the company is working to enhance the Vectra test report to provide patients with their individual risk of radiographic progression in one year.
To view Graph 1: Vectra Predicts Risk of Radiographic Progression in 1 Year,please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/514919cd-81ca-4084-81df-682fedc1784b
Too often people with RA are over- or under-treated because it is difficult for clinicians to accurately measure inflammation and determine the long-term prognosis of RA patients. As a result, some people are at increased risk of rapid radiographic progression, said Jeff Curtis, M.D., M.S., MPH, lead investigator, rheumatologist and Professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham. It is critical that clinicians have reliable information when making treatment decisions. Our study demonstrated that the Vectra score was the strongest predictor of radiographic progression, which may help inform treatment plans and prevent future joint damage.
Title:Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis.Presenter:Jeff Curtis, M.D., M.S., MPH; University of Alabama at Birmingham.Date:Tuesday, Nov. 12, 2019. 9:00-11:00 a.m.Location:Poster 2350.
This study evaluated 30,751 Medicare patients with RA to develop and validate the Vectra CVD score, which predicts risk for a first cardiovascular (CV) event by combining data from Vectra and clinical measures. The primary CV outcome was a composite of three types of CV events heart attack, stroke, and CV death occurring within 3 years from testing. When the performance of the Vectra CVD score was compared to four other CV prediction models, the Vectra CVD score was a significant predictor of CV risk and was superior to all four other models. Importantly, when risk scores were converted to 3-year percentage risk for having a CV event, approximately 80 percent of patients were found to have a moderate or high risk of a CV event over 3 years, based on risk categories analogous to those of the American College of Cardiology/American Heart Association 2018 guidelines (Graph 2).
To view Graph 2: Vectra Predicts Risk of Cardiovascular Events in Patients with RA, please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/c902b4ec-a3c8-439f-9557-0a9b05631a1f
People with rheumatoid arthritis have almost double the risk of heart attack, stroke and atherosclerosis. Traditional CV risk factors alone do not fully explain the increased rates of CV events in RA, and inflammation is a missing component that is measured by the Vectra test, said Dr. Curtis. In this study, the Vectra CVD score effectively predicted CV risk in people with RA. We believe the Vectra CVD score may assist clinicians to more quickly identify patients at high risk for CV events and target interventions that can be potentially life-saving.
The company plans to publish these new data in peer reviewed medical journal and make the Vectra CVD score available to clinicians in fiscal year 2020. Please visit Myriad Autoimmune at booth #1419 to learn more about Vectra. Follow Myriad on Twitter via @myriadgenetics and follow meeting news by using the hashtag #ACR19.
About VectraVectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis. Vectra provides unsurpassed ability to predict radiographic progression and can help guide medical management decisions with the goal of improving patient outcomes. Vectra testing is performed at a state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician five to seven days from shipping of the specimen. Physicians can receive test results by fax or the private web portal, VectraView. For more information on Vectra, please visit: http://www.vectrascore.com.
About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company presenting new data on the Vectra test at the 2019 ACR Annual Meeting; the Vectra test enabling clinicians to tailor precision treatment plans to achieve better outcomes; the Vectra score helping inform treatment plans and prevent future joint damage; the Vectra CVD score assisting clinicians to more quickly identify patients at high risk for CV events and target interventions that can be potentially life-saving; publishing these new data in peer reviewed medical journal; making the Vectra CVD score available to clinicians in fiscal year 2020; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
See the original post:
- Molecular Cardiology Research Lab - Texas Heart Institute - April 15th, 2018 [April 15th, 2018]
- Cardiology - Cardiologists - New York - Montefiore Medical ... - May 7th, 2018 [May 7th, 2018]
- PET/CT - Molecular Imaging - Nuclear MedicinePET-CTPET ... - May 26th, 2018 [May 26th, 2018]
- Molecular Cardiology Centenary Institute - July 16th, 2018 [July 16th, 2018]
- Pediatric Cardiology Fellowship | Pediatrics | University ... - September 25th, 2018 [September 25th, 2018]
- Molecular Multi - 3formulas.com - November 4th, 2018 [November 4th, 2018]
- Society of Nuclear Medicine and Molecular Imaging (SNMMI) - December 20th, 2018 [December 20th, 2018]
- Cardiology 2019 | Cardiology Conferences | Cardiology ... - February 5th, 2019 [February 5th, 2019]
- Cardiology | medicine | Britannica.com - March 18th, 2019 [March 18th, 2019]
- Cardiology | Baylor College of Medicine | Houston, Texas - April 12th, 2019 [April 12th, 2019]
- Cardiology Conferences | Cardiology Meetings | cardiology ... - September 11th, 2019 [September 11th, 2019]
- Nuclear Medicine/Radiopharmaceuticals Market Research Report by Key Players Analysis - Rapid News Network - September 21st, 2019 [September 21st, 2019]
- Macroscopic Imaging Market Growth with Worldwide Industry Analysis to 2019-2027 - Rapid News Network - September 21st, 2019 [September 21st, 2019]
- PET MRI Market to Record an Exponential CAGR by 2025 - Analytics News - September 21st, 2019 [September 21st, 2019]
- In Vitro Diagnostics/IVD Market Rapid Growth with Rising Application Scope by 2026 | Top Players- Danaher, Abbott, Thermo Fisher Scientific Inc,... - September 21st, 2019 [September 21st, 2019]
- Nuclear Imaging Devices Market Industry Outlook, Size, Share, Growth Prospects, Key Opportunities, Trends and Forecast - Wolf Mirror - September 21st, 2019 [September 21st, 2019]
- Heparin-induced Thrombocypenia Treatment Market Size & Share Expanding Across The Globe By 2018 2028 - NewsVarsity - September 21st, 2019 [September 21st, 2019]
- Medical Animation Market is Booming at a CAGR of 8.5% Due To Growing Demand By 2019 - 2026 - US Trade Media - September 21st, 2019 [September 21st, 2019]
- Molecular Imaging Market Will Make a Huge Impact in Near Future - Wolf Mirror - September 21st, 2019 [September 21st, 2019]
- FDA Clears ARTIS icono Family of Angiography Systems From Siemens Healthineers - BioSpace - September 21st, 2019 [September 21st, 2019]
- MR Solutions' liquid helium free PET-MR system firmly on the agenda at WMIC - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Molecular Imaging Devices Market Forecast to 2024 Explored in Latest Research - OnYourDesks - September 21st, 2019 [September 21st, 2019]
- Antibody Production Market Overview on Key Innovations 2023 - TodayTimes - September 24th, 2019 [September 24th, 2019]
- BRIC IVD Market Overview and Scope 2019 to 2024 | Key Players: Roche Diagnostics, Abbott Laboratories, Inc., & more Analytics News - Analytics... - September 24th, 2019 [September 24th, 2019]
- Best Report on Diagnostic Catheter Market 2026 with Major Eminent Key Players Biosense Webster, Inc, Medtronic plc, St. Jude Medical, Boston... - September 24th, 2019 [September 24th, 2019]
- Molecular Imaging Devices Market Industry Shares Report Analysis 2019-2027 - QbnNews - September 24th, 2019 [September 24th, 2019]
- Molecular Imaging Market value projected to expand by 2017 2027 - Analytics News - September 24th, 2019 [September 24th, 2019]
- ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the... - September 24th, 2019 [September 24th, 2019]
- Not for the faint-hearted: why some kids blackout playing video games - The Age - September 24th, 2019 [September 24th, 2019]
- Role of Machine Learning and AI in Precision Medicine - Healthcare Tech Outlook - October 11th, 2019 [October 11th, 2019]
- Here's Why Qiagen Plummeted Today - The Motley Fool - October 11th, 2019 [October 11th, 2019]
- Research Fellow in Muscle Biology job with UNIVERSITY OF LEEDS | 182894 - Times Higher Education (THE) - October 12th, 2019 [October 12th, 2019]
- Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Ind | DMSO - Dove Medical Press - October 17th, 2019 [October 17th, 2019]
- Contrasting of Merit Medical Systems Inc. (MMSI) and BioLife Solutions Inc. (NASDAQ:BLFS) - MS Wkly - October 18th, 2019 [October 18th, 2019]
- Unexpected Growth Seen in Radiopharmaceutical Market Global Forecast to 2025 with Key Players Bayer, Cardinal Health, GE Healthcare, ABT Molecular... - October 18th, 2019 [October 18th, 2019]
- No. 447: Thunderbolts and lasers, with Adelphi's all-world dean and the Father of Rock 'n Roll - Innovate Long Island - October 18th, 2019 [October 18th, 2019]
- Global Molecular Imaging Agents Market Report: Regional Data Analysis by Production, Revenue, Price and Gross Margin - Market Research Writeup - October 22nd, 2019 [October 22nd, 2019]
- Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy - Seeking Alpha - October 29th, 2019 [October 29th, 2019]
- What are the Major Reasons for Rise in Molecular Imaging Market in Recent Period? - The Chicago Sentinel - October 29th, 2019 [October 29th, 2019]
- IVD Market insights size status gross margin and outlook 2019-2025 investigated in the latest research -... - WhaTech - October 30th, 2019 [October 30th, 2019]
- Radiopharmaceutical Market Size, Share 2019 - Growth Insight, Comprehensive Analysis, Top Leading Players, Future Demand and Forecast to 2023 -... - October 30th, 2019 [October 30th, 2019]
- This is the world's smallest commercially available sensor, and it really is tiny! - RedShark News - October 30th, 2019 [October 30th, 2019]
- New model of irregular heartbeat could boost drug efficacy | The Source - Washington University in St. Louis Newsroom - October 30th, 2019 [October 30th, 2019]
- Global In Vitro Diagnostics (IVD) Market Industry Analysis and Forecast (2018-2026) - Maxi Wire - November 7th, 2019 [November 7th, 2019]
- BRIC IVD Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 - Columnist 360 - December 2nd, 2019 [December 2nd, 2019]
- Global Molecular Imaging Agents Market: What it got next? Find out with the latest research available at 'The Market Reports' - Inquiry 24 - December 2nd, 2019 [December 2nd, 2019]
- Molecular Imaging Market to Witness CAGR of 7.5% Rise in Value Share During the Period 2017 2027 - chronicles24 - December 2nd, 2019 [December 2nd, 2019]
- Medical Imaging Equipment Market Global Industry Size, Revenue Growth Development, Business Opportunities, Future Trends, Top Key Players, Market... - December 12th, 2019 [December 12th, 2019]
- PhD Position in Molecular Medicine job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY -NTNU | 188846 - Times Higher Education (THE) - December 12th, 2019 [December 12th, 2019]
- Miss America 2020: Here's a look at the 51 beautiful women who will be competing to take home the crown - MEAWW - December 18th, 2019 [December 18th, 2019]
- Vitro Diagnostics Market: Key Players and Production Information analysis with Forecast 2022 - Downey Magazine - December 18th, 2019 [December 18th, 2019]
- Famed Medical Researcher Partners with Center for Vein Restoration Dr. Armin Foghi - PR Web - December 18th, 2019 [December 18th, 2019]
- Human fat cells tweaked to function like a pacemaker - Times of India - December 18th, 2019 [December 18th, 2019]
- Human fat cells tweaked to work like hearts pacemaker: Study - BusinessLine - December 18th, 2019 [December 18th, 2019]
- Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019 - TCTMD - December 18th, 2019 [December 18th, 2019]
- Global Nuclear Imaging Equipment Market 2019-2023 | Evolving Opportunities With Canon Inc. and Mediso Ltd. | Technavio - Business Wire - January 12th, 2020 [January 12th, 2020]
- Isothermal Nucleic Acid Amplification Technology Market Worth $3.3 Billion in 2024 - Exclusive Report by MarketsandMarkets - PRNewswire - January 16th, 2020 [January 16th, 2020]
- No one knew why some Amish children were dying suddenly. Now researchers have some answers - The Albany Herald - January 16th, 2020 [January 16th, 2020]
- Quantum Genomics to Present at the Gordon Research Conference 2020 Dedicated to the Renin Angiotensin Aldosterone System - Yahoo Finance - January 16th, 2020 [January 16th, 2020]
- Mount Sinai Research Finds that Heterogeneity of Liver Cancer Cells Help Explain Tumor Progression in Patients - PR Web - January 20th, 2020 [January 20th, 2020]
- Medical Imaging Equipment Market Size 2020, Trends, Industry Share, Business Opportunities and Demand Forecast to 2025 - Medical Market News - January 31st, 2020 [January 31st, 2020]
- Invicro Scientists Work on Imaging Synaptic Density in Schizophrenia Published in Nature Communications - Yahoo Finance - January 31st, 2020 [January 31st, 2020]
- 2020 In Vitro Diagnostics (IVD) Market Report- Growth, Challenges, Attractive Valuation and Top Key Players - Science of Change - February 1st, 2020 [February 1st, 2020]
- IVD Market To Inspect Growth Trends during Forecast Period 2019 to 2026 |Siemens, Danaher Corporation, Becton - Expedition 99 - February 1st, 2020 [February 1st, 2020]
- Invicro Scientists Work on Imaging Synaptic Density in Schizophrenia Published in Nature Communications - Business Wire - February 1st, 2020 [February 1st, 2020]
- PET Radiopharmaceuticals Market Report (2019-2025) | The demand for the Market will drastically increase in the Future - Chronicle 99 - February 17th, 2020 [February 17th, 2020]
- In Vitro Diagnostics (IVD) and Laboratory Developed Tests for Autoimmune Diseases Market With Top Countries Data Analysis and Forecast 2025 by Recent... - February 17th, 2020 [February 17th, 2020]
- North American Nuclear Medicine Market Expected to Reach USD 2.7 Billion by 2024 with a CAGR of 4.1% - ResearchAndMarkets.com - Business Wire - February 17th, 2020 [February 17th, 2020]
- Biologic And Medical Imaging Reagents Market to Make Great Impact in near Future by -2022 - Kentucky Journal 24 - February 17th, 2020 [February 17th, 2020]
- Global In Vitro Diagnostics (IVD) Industry, Forecast to 2027 - Molecular Diagnostics to Exhibit the Fastest Growth - Yahoo Finance - March 8th, 2020 [March 8th, 2020]
- GeneDx Celebrates 20 Year History as Pioneer In Genetic Sequencing and Testing - BioBuzz - March 22nd, 2020 [March 22nd, 2020]
- Contract Development and Manufacturing Organization Market worth USD 278.98 Billion by 2026; Increasing Demand for Pharmaceutical Products Will Aid... - March 24th, 2020 [March 24th, 2020]
- Outlook into the Global Hybrid Imaging Market to 2025 - by Application, Type, End Use and Region - Yahoo Finance - March 24th, 2020 [March 24th, 2020]
- Smoking cessation counseling and e-cigs may be effective for breaking the habit - Mental Daily - April 1st, 2020 [April 1st, 2020]
- How daylight saving time affects health, and why Turkey was right to abandon it - Daily Sabah - April 1st, 2020 [April 1st, 2020]
- Single-Photon Emission Computed Tomography Market by Key Players, Regions, Type and Application, Forecast to 2027 - Jewish Life News - April 1st, 2020 [April 1st, 2020]
- Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients - TCTMD - April 1st, 2020 [April 1st, 2020]
- In-Vitro Diagnostics Market 2020 | Top Business Growing Strategies, Technological Innovation and Emerging Trends of Outlook To 2028 - Publicist360 - April 10th, 2020 [April 10th, 2020]
- Abbott's Point-of-Care COVID-19 Test Delivers Results Within Minutes - The Cardiology Advisor - April 10th, 2020 [April 10th, 2020]
- Molecular Imaging Market: Drivers, Restraints, Opportunities, and Threats (20192025) - Science In Me - April 10th, 2020 [April 10th, 2020]